| 79.97 0 (0%) | 02-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 93.4 | 1-year : | 109.09 |
| Resists | First : | 79.97 | Second : | 93.4 |
| Pivot price | 79.83  |
|||
| Supports | First : | 79.54 | Second : | 79.29 |
| MAs | MA(5) : | 79.94 |
MA(20) : | 79.78 |
| MA(100) : | 58.25 |
MA(250) : | 51.08 |
|
| MACD | MACD : | 2.5  |
Signal : | 3.3 |
| %K %D | K(14,3) : | 96.8 |
D(3) : | 95 |
| RSI | RSI(14): 79.6 | |||
| 52-week | High : | 79.97 | Low : | 36.72 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ NARI ] has closed below upper band by 19.4%. Bollinger Bands are 96.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 80.09 - 80.49 | 80.49 - 80.82 |
| Low: | 79.02 - 79.45 | 79.45 - 79.81 |
| Close: | 79.34 - 80.01 | 80.01 - 80.57 |
Inari Medical, Inc., a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism. It also offers FlowSaver; FlowStasis, a large bore suture retention device designed to address various aspects of venous access site; and FlowTriever 2, a new disk shape designed to capture and remove wall adherent clot and shorten treatment. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.
Wed, 19 Feb 2025
Stryker's Strategic Move: How Inari's Blood Clot Solutions Transform Its Market Position - Stock Titan
Wed, 19 Feb 2025
Stryker completes acquisition of Inari Medical, Inc., providing entry into the high-growth peripheral vascular segment - GlobeNewswire
Fri, 17 Jan 2025
Stryker Launches $80 Per Share Cash Tender Offer for Inari Medical Acquisition - Stock Titan
Fri, 17 Jan 2025
Here’s Why Inari Medical, Inc. (NARI) Is Skyrocketing - Yahoo Finance
Tue, 07 Jan 2025
Inari Medical (NARI) Soars 30.6%: Is Further Upside Left in the Stock? - Yahoo Finance
Tue, 07 Jan 2025
Inari Shares Skyrocket As Stryker Will Acquire Medical Device Maker for $4.9B - Investopedia
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 59 (M) |
| Shares Float | 53 (M) |
| Held by Insiders | 9 (%) |
| Held by Institutions | 95.5 (%) |
| Shares Short | 2,480 (K) |
| Shares Short P.Month | 3,840 (K) |
| EPS | -1.36 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.44 |
| Profit Margin | -13.7 % |
| Operating Margin | -4.4 % |
| Return on Assets (ttm) | -3.3 % |
| Return on Equity (ttm) | -17.8 % |
| Qtrly Rev. Growth | 21.3 % |
| Gross Profit (p.s.) | 8.51 |
| Sales Per Share | 9.81 |
| EBITDA (p.s.) | -0.45 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 14 (M) |
| Levered Free Cash Flow | 87 (M) |
| PE Ratio | -59.24 |
| PEG Ratio | 0 |
| Price to Book value | 10.74 |
| Price to Sales | 8.15 |
| Price to Cash Flow | 330.25 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|